Time trends in survival from cancer of unknown primary: Small steps forward

被引:28
作者
Riihimaki, M. [1 ,2 ]
Hemminki, A. [3 ,4 ]
Sundquist, K. [2 ,5 ]
Hemminki, K. [1 ,2 ]
机构
[1] German Canc Res Ctr, Div Mol Genet Epidemiol, D-69120 Heidelberg, Germany
[2] Lund Univ, Ctr Primary Hlth Care Res, Malmo, Sweden
[3] Univ Helsinki, Canc Gene Therapy Grp, Transplantat Lab, FIN-00290 Helsinki, Finland
[4] Univ Helsinki, Dept Pathol, Haartman Inst, FIN-00290 Helsinki, Finland
[5] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Palo Alto, CA 94304 USA
关键词
Cancer of unknown primary; CUP; Survival; Trend; PRIMARY SITE; CARCINOMA; DEATH; END; METASTASIS; THERAPY; HISTORY; ORIGIN; ORGANS;
D O I
10.1016/j.ejca.2013.02.022
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cancer of unknown primary (CUP) is a fatal cancer for which incidence trends have changed but detailed survival trends remain unexplored. These could point out successful diagnostic and therapeutic approaches. We investigate survival trends in CUP according to histology, locations of metastases and site-specific causes of death. Patients and methods: A total of 20,523 CUP patients with nodal and extranodal metastases were identified from the Swedish Cancer Registry. Hazard ratios (HRs) were estimated, comparing three different time periods (1987-1993, 1994-2000 and 2001-2008) with respect to histological subtype, CUP location and the cause of death. Results: Survival for patients with CUP increased over the study period (HR = 0.91 [95% confidence interval (CI): 0.78-0.84], p < 0.001 for trend). Adenocarcinoma was the only histology associated with increased survival (0.78 [0.74-0.82], p < 0.001 for trend). Survival was improved most clearly for CUP of the pelvis (0.55 [0.36-0.83]), peritoneum (0.58 [0.53-0.65]) and nervous system (0.46 [0.29-0.72]). Survival improved substantially in patients with ovarian (0.57 [0.46-0.70]), peritoneal (0.39 [0.24-0.65]) and biliary system cancers (0.67 [0.52-0.87]). Kaplan-Meier curves showed significant survival gains for all CUP and adenocarcinoma patients (p < 0.001). Conclusions: Over time, survival for patients with CUP increased for adenocarcinoma and for CUP of the pelvis, peritoneum and nervous system. Survival trends in CUP may be related to (1) similar trends in other common metastatic tumours, particularly pancreatic and hepatobiliary cancers, which are common 'hidden' primaries for CUP, (2) earlier detection and (3) advances in the management of metastatic cancers. The improvement in survival at specific locations suggests true therapeutic gains. (c) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2403 / 2410
页数:8
相关论文
共 38 条
[1]   UNKNOWN PRIMARY-CARCINOMA - NATURAL-HISTORY AND PROGNOSTIC FACTORS IN 657 CONSECUTIVE PATIENTS [J].
ABBRUZZESE, JL ;
ABBRUZZESE, MC ;
HESS, KR ;
RABER, MN ;
LENZI, R ;
FROST, P .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (06) :1272-1280
[2]   Incidence of cancer of unknown primary in Sweden: analysis by location of metastasis [J].
Bevier, Melanie ;
Sundquist, Jan ;
Hemminki, Kari .
EUROPEAN JOURNAL OF CANCER PREVENTION, 2012, 21 (06) :596-601
[3]   Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression [J].
Bissell, Mina J. ;
Hines, William C. .
NATURE MEDICINE, 2011, 17 (03) :320-329
[4]   Cancer of unknown primary:: clinicopathologic correlations [J].
Blaszyk, H ;
Hartmann, A ;
Björnsson, J .
APMIS, 2003, 111 (12) :1089-1094
[5]  
Bruzzone MG, 2012, Q J NUCL MED MOL IM, V56, P112
[6]   Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Fizazi, K. ;
Greco, F. A. ;
Pavlidis, N. ;
Pentheroudakis, G. .
ANNALS OF ONCOLOGY, 2011, 22 :vi64-vi68
[7]   Role of angiogenesis in tumor growth and metastasis [J].
Folkman, J .
SEMINARS IN ONCOLOGY, 2002, 29 (06) :15-18
[8]   Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis [J].
Golfinopoulos, Vassilis ;
Pentheroudakis, George ;
Salanti, Georgia ;
Nearchou, Andreas D. ;
Ioannidis, John P. A. ;
Pavlidis, Nicholas .
CANCER TREATMENT REVIEWS, 2009, 35 (07) :570-573
[9]   Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes [J].
Greco, F. A. ;
Oien, K. ;
Erlander, M. ;
Osborne, R. ;
Varadhachary, G. ;
Bridgewater, J. ;
Cohen, D. ;
Wasan, H. .
ANNALS OF ONCOLOGY, 2012, 23 (02) :298-304
[10]   Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: The Minnie Pearl Cancer Research Network [J].
Hainsworth, John D. ;
Spigel, David R. ;
Farley, Cindy ;
Thompson, Dana S. ;
Shipley, Dianna L. ;
Greco, F. Anthony .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1747-1752